Tags

Type your tag names separated by a space and hit enter

[Dapoxetine for premature ejaculation: Advances in clinical studies].
Zhonghua Nan Ke Xue. 2015 Oct; 21(10):931-6.ZN

Abstract

Premature ejaculation (PE) is a most common sexual dysfunction, for which dapoxetine, a novel selective serotonin (5-HT) re-uptake inhibitor (SSRI), is the only licensed oral medicine at present. With the advantages of fast absorption, rapid action, on-demand medication, and short half-life time, dapoxetine has been proved by clinical trials to be effective in prolonging the intravaginal ejaculation latency time (IELT) and improving the overall condition of PE patients in various areas and populations. Compared with the traditional SSRIs, dapoxetine has a better safety and tolerability. The most frequently reported dapoxetine-related adverse events include nausea, diarrhea, headache and dizziness, but with very few severe or serious cases.

Authors

Zhou TY
No affiliation info available
Li YF
No affiliation info available

MeSH

BenzylaminesBiomedical ResearchEjaculationHumansMaleNaphthalenesPremature EjaculationReaction TimeSelective Serotonin Reuptake InhibitorsTreatment Outcome

Pub Type(s)

Journal Article

Language

chi

PubMed ID

26665685

Citation

Zhou, Ting-you, and Yan-feng Li. "[Dapoxetine for Premature Ejaculation: Advances in Clinical Studies]." Zhonghua Nan Ke Xue = National Journal of Andrology, vol. 21, no. 10, 2015, pp. 931-6.
Zhou TY, Li YF. [Dapoxetine for premature ejaculation: Advances in clinical studies]. Zhonghua Nan Ke Xue. 2015;21(10):931-6.
Zhou, T. Y., & Li, Y. F. (2015). [Dapoxetine for premature ejaculation: Advances in clinical studies]. Zhonghua Nan Ke Xue = National Journal of Andrology, 21(10), 931-6.
Zhou TY, Li YF. [Dapoxetine for Premature Ejaculation: Advances in Clinical Studies]. Zhonghua Nan Ke Xue. 2015;21(10):931-6. PubMed PMID: 26665685.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Dapoxetine for premature ejaculation: Advances in clinical studies]. AU - Zhou,Ting-you, AU - Li,Yan-feng, PY - 2015/12/16/entrez PY - 2015/12/17/pubmed PY - 2016/3/25/medline SP - 931 EP - 6 JF - Zhonghua nan ke xue = National journal of andrology JO - Zhonghua Nan Ke Xue VL - 21 IS - 10 N2 - Premature ejaculation (PE) is a most common sexual dysfunction, for which dapoxetine, a novel selective serotonin (5-HT) re-uptake inhibitor (SSRI), is the only licensed oral medicine at present. With the advantages of fast absorption, rapid action, on-demand medication, and short half-life time, dapoxetine has been proved by clinical trials to be effective in prolonging the intravaginal ejaculation latency time (IELT) and improving the overall condition of PE patients in various areas and populations. Compared with the traditional SSRIs, dapoxetine has a better safety and tolerability. The most frequently reported dapoxetine-related adverse events include nausea, diarrhea, headache and dizziness, but with very few severe or serious cases. SN - 1009-3591 UR - https://www.unboundmedicine.com/medline/citation/26665685/[Dapoxetine_for_premature_ejaculation:_Advances_in_clinical_studies]_ DB - PRIME DP - Unbound Medicine ER -